![](https://endpts.com/wp-content/uploads/2022/11/Jennifer-Buell-1.jpg)
MiNK Therapeutics CEO Jennifer Buell
In waning Covid market, MiNK unveils data on natural killer T cell therapy for ARDS, pending contract with DARPA
In an SITC poster, Agenus’ spinout MiNK Therapeutics dropped the results of a Phase I/II study of its lead candidate, made from rare immune cells …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.